Skip to main content

Featured

Daily Markets Update: TSX Hits 4-Month Low, Anthropic IPO Lifts Futures

  CANADIAN MONEY BRIEF Daily Markets Update Thursday, November 19, 2026  |  Wednesday’s closes, plus Thursday’s Asian session and U.S. futures The short version: A commodity rout hit Canada hardest. The S&P/TSX Composite Index lost 737.25 points, or 2.09%, to close at 34,578.05, its lowest finish in more than four months, as gold, copper and oil all fell sharply. On Wall Street, the Dow dropped 561 points and the S&P 500 notched a fifth straight loss, while the Nasdaq edged higher even after Nvidia’s post-earnings pop faded. Thursday opens on a brighter note: U.S. futures are up roughly 1% to 2% after Anthropic priced the largest IPO on record, ahead of its Nasdaq debut. Market Snapshot Index / Asset Level Change S&P/TSX Composite 34,578.05 ▼ -2.09% Dow Jones Industrial Average 50,198.17 ▼ -1.11% S&P 500 7,323.63 ▼ -0.23% Nasdaq Composite 24,429.88 ▲ +0.42% STOXX Europe 600 644.05 ▼ -1.03% Nikkei 225 (Thu.) 59,444.21 ▲ +0.71% Hang Seng (Thu.) 22,841.62 ▼ ...

article

Pharmacare in Canada: A Dream or a Reality?

 


The fate of Canada's pharmacare plan is uncertain as the federal government faces challenges in implementing a universal drug coverage program, even if a bill to create one passes in Parliament. Bill C-213, the Canada Pharmacare Act, aims to establish a national framework for pharmacare that would ensure all Canadians have access to prescription drugs based on their medical needs, not their ability to pay. 

However, the bill does not specify how the program would be funded, administered or negotiated with the provinces and territories, leaving many questions unanswered about the feasibility and cost-effectiveness of pharmacare. Some experts and stakeholders have expressed doubts about whether Ottawa has the political will, the constitutional authority and the fiscal capacity to deliver on its promise of pharmacare, especially in the wake of the COVID-19 pandemic that has strained the health care system and the public purse.

Comments